<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;fc=20230708114047&amp;ff=20230803022755&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;fc=20230708114047&amp;ff=20230803022755&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Thu, 03 Aug 2023 06:27:56 +0000</lastbuilddate>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Novel macrophage targets for the treatment of atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532948/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Aug 2. doi: 10.1038/s41569-023-00918-7. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532948/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37532948</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00918-7>10.1038/s41569-023-00918-7</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532948</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Novel macrophage targets for the treatment of atrial fibrillation</dc:title>
<dc:identifier>pmid:37532948</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00918-7</dc:identifier>
</item>
<item>
<title>REPLY: Risk of Surgical Mitral Valve Repair for Primary Mitral Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532430/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):e47-e48. doi: 10.1016/j.jacc.2023.06.004.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532430/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37532430</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.004>10.1016/j.jacc.2023.06.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532430</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Vinay Badhwar</dc:creator>
<dc:creator>J Hunter Mehaffey</dc:creator>
<dc:creator>Robert H Habib</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>REPLY: Risk of Surgical Mitral Valve Repair for Primary Mitral Regurgitation</dc:title>
<dc:identifier>pmid:37532430</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.004</dc:identifier>
</item>
<item>
<title>Surgical Risk Scores in Mitral Valve Surgery and the Danger of Channeling Bias</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532429/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):e45. doi: 10.1016/j.jacc.2023.04.058.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532429/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37532429</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.04.058>10.1016/j.jacc.2023.04.058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532429</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Jules R Olsthoorn</dc:creator>
<dc:creator>Niels Verberkmoes</dc:creator>
<dc:creator>Peyman Sardari Nia</dc:creator>
<dc:creator>Samuel Heuts</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Surgical Risk Scores in Mitral Valve Surgery and the Danger of Channeling Bias</dc:title>
<dc:identifier>pmid:37532429</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.04.058</dc:identifier>
</item>
<item>
<title>Surgical Mitral Valve Repair: Excellent Outcomes, But for the Selected Few?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532428/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):e43. doi: 10.1016/j.jacc.2023.02.054.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532428/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37532428</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.02.054>10.1016/j.jacc.2023.02.054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532428</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Mohamad Alkhouli</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Surgical Mitral Valve Repair: Excellent Outcomes, But for the Selected Few?</dc:title>
<dc:identifier>pmid:37532428</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.02.054</dc:identifier>
</item>
<item>
<title>Gender Disparity in Citations and Altmetric Attention Scores in High-Impact Cardiology Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532427/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):572-573. doi: 10.1016/j.jacc.2023.05.044.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532427/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37532427</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.044>10.1016/j.jacc.2023.05.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532427</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Kristen N Brown</dc:creator>
<dc:creator>Ridhima Goel</dc:creator>
<dc:creator>Sana Soman</dc:creator>
<dc:creator>Essaq Khan</dc:creator>
<dc:creator>Lina Ya'Qoub</dc:creator>
<dc:creator>Vinicius Calsavara</dc:creator>
<dc:creator>Dee Dee Wang</dc:creator>
<dc:creator>Poonam Velagapudi</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Martha Gulati</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Gender Disparity in Citations and Altmetric Attention Scores in High-Impact Cardiology Journals</dc:title>
<dc:identifier>pmid:37532427</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.044</dc:identifier>
</item>
<item>
<title>Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532426/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>Despite worsening heart failure (HF) being extremely common, expensive, and associated with substantial risk of death, there remain no dedicated clinical practice guidelines for the specific management of these patients. The lack of a management guideline is despite a rapidly evolving evidence-base, as a number of recent clinical trials have demonstrated multiple therapies to be safe and efficacious in this high-risk population. Herein, we propose a framework for treating worsening HF with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):559-571. doi: 10.1016/j.jacc.2023.04.057.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite worsening heart failure (HF) being extremely common, expensive, and associated with substantial risk of death, there remain no dedicated clinical practice guidelines for the specific management of these patients. The lack of a management guideline is despite a rapidly evolving evidence-base, as a number of recent clinical trials have demonstrated multiple therapies to be safe and efficacious in this high-risk population. Herein, we propose a framework for treating worsening HF with reduced ejection fraction with the sense of urgency it deserves. This includes treating congestion; managing precipitants; and establishing a foundation of rapid-sequence, simultaneous, and/or in-hospital initiation of quadruple medical therapy for HF with reduced ejection fraction, with the top priority being at least low doses of all 4 medications. Moreover, to maximally reduce residual clinical risk, we further propose consideration of upfront simultaneous use of vericiguat (ie, quintuple medical therapy) and administration of intravenous iron for those who are iron deficient.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532426/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37532426</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.04.057>10.1016/j.jacc.2023.04.057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532426</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Stephen J Greene</dc:creator>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:creator>Jasper J Brugts</dc:creator>
<dc:creator>Justin A Ezekowitz</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:creator>Finn Gustafsson</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Lars H Lund</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:creator>Burkert Pieske</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Natalie Skopicki</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Shelley Zieroth</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3</dc:title>
<dc:identifier>pmid:37532426</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.04.057</dc:identifier>
</item>
<item>
<title>Bridging Treatment Implementation Gaps in Patients With Heart Failure: JACC Focus Seminar 2/3</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532425/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>Heart failure (HF) is a leading cause of death and disability in older adults. Despite decades of high-quality evidence to support their use, guideline-directed medical therapies (GDMTs) that reduce death and disease burden in HF have been suboptimally implemented. Approaches to closing care gaps have focused largely on strategies proven to be ineffective, whilst effective interventions shown to improve GDMT uptake have not been instituted. This review synthesizes implementation interventions...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):544-558. doi: 10.1016/j.jacc.2023.05.050.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Heart failure (HF) is a leading cause of death and disability in older adults. Despite decades of high-quality evidence to support their use, guideline-directed medical therapies (GDMTs) that reduce death and disease burden in HF have been suboptimally implemented. Approaches to closing care gaps have focused largely on strategies proven to be ineffective, whilst effective interventions shown to improve GDMT uptake have not been instituted. This review synthesizes implementation interventions that increase the uptake of GDMT, discusses barriers and facilitators of implementation, summarizes conceptual frameworks in implementation science that could improve knowledge uptake, and offers suggestions for trial design that could better facilitate end-of-trial implementation. We propose an evidence-to-care conceptual model that could foster the simultaneous generation of evidence and long-term implementation. By adopting principles of implementation science, policymakers, researchers, and clinicians can help reduce the burden of HF on patients and health care systems worldwide.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532425/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37532425</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.050>10.1016/j.jacc.2023.05.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532425</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Mohamed B Jalloh</dc:creator>
<dc:creator>Tauben Averbuch</dc:creator>
<dc:creator>Prashanth Kulkarni</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Robert W Yeh</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Khadijah Breathett</dc:creator>
<dc:creator>C Michael Gibson</dc:creator>
<dc:creator>Harriette G C Van Spall</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bridging Treatment Implementation Gaps in Patients With Heart Failure: JACC Focus Seminar 2/3</dc:title>
<dc:identifier>pmid:37532425</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.050</dc:identifier>
</item>
<item>
<title>Implementing Guideline-Directed Medical Therapy for Heart Failure: JACC Focus Seminar 1/3</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532424/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>Despite the availability of lifesaving guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), there remain major gaps in utilization of these therapies among eligible patients. Simultaneous with these gaps in quality of care, HFrEF continues as a leading cause of death and hospitalization with associated clinical risk far exceeding most other cardiovascular and noncardiovascular conditions. In the context of this urgent need to improve provision of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):529-543. doi: 10.1016/j.jacc.2023.03.430.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite the availability of lifesaving guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), there remain major gaps in utilization of these therapies among eligible patients. Simultaneous with these gaps in quality of care, HFrEF continues as a leading cause of death and hospitalization with associated clinical risk far exceeding most other cardiovascular and noncardiovascular conditions. In the context of this urgent need to improve provision of appropriate therapy, multiple lines of evidence support various implementation strategies. Such strategies include in-hospital initiation of GDMT, simultaneous or rapid sequence initiation of GDMT, participation in quality improvement registries to assess site performance and provide feedback, multidisciplinary titration clinics, virtual consult teams, reduction of cost-sharing, remote algorithm-based medication optimization, electronic health record-based interventions, and direct-to-patient educational initiatives. This review describes and contextualizes the evidence surrounding each of these potential avenues for improving use of foundational GDMTs for patients with HFrEF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532424/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37532424</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.03.430>10.1016/j.jacc.2023.03.430</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532424</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Harsh Patolia</dc:creator>
<dc:creator>Muhammad Shahzeb Khan</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Stephen J Greene</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Implementing Guideline-Directed Medical Therapy for Heart Failure: JACC Focus Seminar 1/3</dc:title>
<dc:identifier>pmid:37532424</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.03.430</dc:identifier>
</item>
<item>
<title>GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532423/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):526-528. doi: 10.1016/j.jacc.2023.06.005.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532423/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37532423</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.005>10.1016/j.jacc.2023.06.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532423</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Vanita R Aroda</dc:creator>
<dc:creator>Liana K Billings</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection</dc:title>
<dc:identifier>pmid:37532423</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.005</dc:identifier>
</item>
<item>
<title>GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532422/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In patients with T2D and cardiovascular disease, GLP-1 RAs reduced cardiovascular events independently of SGLT2 inhibitor use. These findings suggest that the combination of GLP-1 RAs with SGLT2 inhibitors may further reduce cardiovascular risk. Clinical trials with combination therapy are needed.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):517-525. doi: 10.1016/j.jacc.2023.05.048.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors and GLP-1 receptor agonists (GLP-1 RAs) reduce adverse cardiovascular outcomes in type 2 diabetes (T2D). However, the efficacy of combination therapy is unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to evaluate the effects of GLP-1 RAs on cardiovascular outcomes in patients with T2D treated with or without SGLT2 inhibitors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Post hoc analysis of Harmony Outcomes (Albiglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease) evaluating the effect of albiglutide in T2D with cardiovascular disease by background SGLT2 inhibitor use. Additionally, a trial-level meta-analysis of Harmony Outcomes and AMPLITUDE-O (Effect of Efpeglenatide on Cardiovascular Outcomes), which evaluated T2D with cardiovascular or renal disease, was performed, combining the treatment effect estimates according to SGLT2 inhibitor use.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 9,462 participants in Harmony Outcomes, 575 (6.1%) were treated with SGLT2 inhibitors at baseline. The effect of albiglutide on reducing the composite of cardiovascular death, myocardial infarction, or stroke (major adverse cardiovascular events) was consistent with or without SGLT2 inhibitors (P interaction = 0.70). The effect of albiglutide on secondary outcomes and adverse events was not modified by SGLT2 inhibitors. A meta-analysis of Harmony Outcomes and AMPLITUDE-O included 13,538 patients, of whom 1,193 (8.8%) used SGLT2 inhibitors. Compared to placebo, GLP1-RAs reduced major adverse cardiovascular events without effect modification by SGLT2 inhibitor use (HR: 0.77; 95% CI: 0.68-0.87 without SGLT2 inhibitors; and HR: 0.78; 95% CI: 0.49-1.24 with SGLT2 inhibitors) (P for interaction = 0.95) and reduced heart failure hospitalization (HR: 0.72; 95% CI: 0.55-0.92 vs HR: 0.34; 95% CI: 0.12-0.96) (P for interaction = 0.18).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with T2D and cardiovascular disease, GLP-1 RAs reduced cardiovascular events independently of SGLT2 inhibitor use. These findings suggest that the combination of GLP-1 RAs with SGLT2 inhibitors may further reduce cardiovascular risk. Clinical trials with combination therapy are needed.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532422/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37532422</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.048>10.1016/j.jacc.2023.05.048</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532422</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>João Sérgio Neves</dc:creator>
<dc:creator>Marta Borges-Canha</dc:creator>
<dc:creator>Francisco Vasques-Nóvoa</dc:creator>
<dc:creator>Jennifer B Green</dc:creator>
<dc:creator>Lawrence A Leiter</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Davide Carvalho</dc:creator>
<dc:creator>Adelino Leite-Moreira</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Stefano Del Prato</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>João Pedro Ferreira</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes</dc:title>
<dc:identifier>pmid:37532422</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.048</dc:identifier>
</item>
<item>
<title>Ebstein Anomaly: More Than Just a Tricuspid Valve Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532421/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):514-516. doi: 10.1016/j.jacc.2023.05.041.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532421/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37532421</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.041>10.1016/j.jacc.2023.05.041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532421</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Anne M Valente</dc:creator>
<dc:creator>David M Harrild</dc:creator>
<dc:creator>Rebecca S Beroukhim</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Ebstein Anomaly: More Than Just a Tricuspid Valve Issue</dc:title>
<dc:identifier>pmid:37532421</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.041</dc:identifier>
</item>
<item>
<title>Prognostic Performance of Right Ventricular Global Longitudinal Strain Measurements in Patients With Ebstein Anomaly</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532420/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: These data support the use of RVGLS for risk stratification in Ebstein anomaly, and further studies are required to assess how interventions may affect different patients according to risk stratification.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):503-513. doi: 10.1016/j.jacc.2023.05.045.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: There are limited data on the prognostic role of right ventricular global longitudinal strain (RVGLS) in patients with Ebstein anomaly.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to assess the relationship between RVGLS and mortality and to compare prognostic performance of RVGLS with conventional echocardiographic indices of right ventricular (RV) systolic function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study identified adults with Ebstein anomaly with echocardiographic assessment of RV systolic function (RVGLS, RV fractional area change [RVFAC], RV tissue Doppler systolic velocity [RV s'], and tricuspid annular plane systolic excursion [TAPSE]) from 2003 to 2020. For ease of presentation, RVGLS was modeled as absolute values (ie, without the negative sign).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 620 patients (median age 37 years; men 261 [42%]), the mean absolute RVGLS, RVFAC, RV s', and TAPSE were 18% ± 5%, 32% ± 9%, 14 ± 6 cm/s, and 22 ± 8 mm, respectively. There were correlations between absolute RVGLS and RVFAC (r = 0.71; P &lt; 0.001), between absolute RVGLS and RV s' (r = 0.41; P = 0.03), and between absolute RVGLS and TAPSE (r = 0.44; P = 0.002). Of 620 patients, 47 (8%) died during follow-up, and 34 of these deaths were cardiovascular. Absolute RVGLS was independently associated with all-cause mortality (adjusted HR: 0.94; 95% CI: 0.92-0.96 per unit increase) and cardiovascular mortality (adjusted HR: 0.92; 95% CI: 0.90-0.94 per unit increase). Absolute RVGLS had superior prognostic power (ie, ability to predict mortality) as compared with RVFAC, RV s', or TAPSE.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These data support the use of RVGLS for risk stratification in Ebstein anomaly, and further studies are required to assess how interventions may affect different patients according to risk stratification.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532420/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37532420</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.045>10.1016/j.jacc.2023.05.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532420</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Alexander C Egbe</dc:creator>
<dc:creator>William R Miranda</dc:creator>
<dc:creator>C Charles Jain</dc:creator>
<dc:creator>Kartik Andi</dc:creator>
<dc:creator>Omar Abozied</dc:creator>
<dc:creator>Ahmed K Younis</dc:creator>
<dc:creator>Sriharsha Kandlakunta</dc:creator>
<dc:creator>Abdalla A Salama</dc:creator>
<dc:creator>Elizabeth H Stephens</dc:creator>
<dc:creator>Heidi M Connolly</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prognostic Performance of Right Ventricular Global Longitudinal Strain Measurements in Patients With Ebstein Anomaly</dc:title>
<dc:identifier>pmid:37532420</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.045</dc:identifier>
</item>
<item>
<title>Right Heart Dysfunction in HFpEF: More Complex and More Common Than We Thought</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532419/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):500-502. doi: 10.1016/j.jacc.2023.05.049.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532419/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37532419</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.049>10.1016/j.jacc.2023.05.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532419</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Julia Grapsa</dc:creator>
<dc:creator>Sean P Pinney</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Right Heart Dysfunction in HFpEF: More Complex and More Common Than We Thought</dc:title>
<dc:identifier>pmid:37532419</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.049</dc:identifier>
</item>
<item>
<title>The Evolving Role of Cardiac Troponin: From Acute to Chronic Coronary Syndromes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532418/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):486-488. doi: 10.1016/j.jacc.2023.05.047.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532418/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37532418</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.047>10.1016/j.jacc.2023.05.047</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532418</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Yader Sandoval</dc:creator>
<dc:creator>Allan S Jaffe</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Evolving Role of Cardiac Troponin: From Acute to Chronic Coronary Syndromes</dc:title>
<dc:identifier>pmid:37532418</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.047</dc:identifier>
</item>
<item>
<title>High-Sensitivity Cardiac Troponin for Risk Assessment in Patients With Chronic Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37532417/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In patients with chronic coronary artery disease, cardiac troponin predicts risk of myocardial infarction or cardiovascular death independent of cardiovascular risk factors and disease severity. Further studies are required to evaluate whether routine testing could inform the selection of high-risk patients for treatment intensification. (Myocardial Injury in Patients Referred for Coronary Angiography [MICA]; ISRCTN15620297).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 8;82(6):473-485. doi: 10.1016/j.jacc.2023.05.046.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac troponin is used for risk stratification of patients with acute coronary syndromes; however, the role of testing in other settings remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The aim of this study was to evaluate whether cardiac troponin testing could enhance risk stratification in patients with chronic coronary artery disease independent of disease severity and conventional risk measures.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In a prospective cohort of consecutive patients with symptoms suggestive of stable angina attending for outpatient coronary angiography, high-sensitivity cardiac troponin I was measured before angiography, and clinicians were blinded to the results. The primary outcome was myocardial infarction or cardiovascular death during follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In 4,240 patients (age 66 years [IQR: 59-73 years], 33% female), coronary artery disease was identified in 3,888 (92%) who had 255 (6%) primary outcome events during a median follow-up of 2.4 years (IQR: 1.3-3.6 years). In patients with coronary artery disease, troponin concentrations were 2-fold higher in those with an event compared with those without (6.7 ng/L [IQR: 3.2-14.2 ng/L] vs 3.3 ng/L [IQR: 1.7-6.6 ng/L]; P &lt; 0.001). Troponin concentrations were associated with the primary outcome after adjusting for cardiovascular risk factors and coronary artery disease severity (adjusted HR: 2.3; 95% CI: 1.7-3.0, log<sub>10</sub> troponin; P &lt; 0.001). A troponin concentration >;10 ng/L identified patients with a 50% increase in the risk of myocardial infarction or cardiovascular death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with chronic coronary artery disease, cardiac troponin predicts risk of myocardial infarction or cardiovascular death independent of cardiovascular risk factors and disease severity. Further studies are required to evaluate whether routine testing could inform the selection of high-risk patients for treatment intensification. (Myocardial Injury in Patients Referred for Coronary Angiography [MICA]; ISRCTN15620297).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37532417/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37532417</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.05.046>10.1016/j.jacc.2023.05.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37532417</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Ryan Wereski</dc:creator>
<dc:creator>Philip Adamson</dc:creator>
<dc:creator>Nur Shazlin Shek Daud</dc:creator>
<dc:creator>Michael McDermott</dc:creator>
<dc:creator>Caelan Taggart</dc:creator>
<dc:creator>Anda Bularga</dc:creator>
<dc:creator>Dorien M Kimenai</dc:creator>
<dc:creator>Mathew T H Lowry</dc:creator>
<dc:creator>Chris Tuck</dc:creator>
<dc:creator>Atul Anand</dc:creator>
<dc:creator>David J Lowe</dc:creator>
<dc:creator>Andrew R Chapman</dc:creator>
<dc:creator>Nicholas L Mills</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>High-Sensitivity Cardiac Troponin for Risk Assessment in Patients With Chronic Coronary Artery Disease</dc:title>
<dc:identifier>pmid:37532417</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.05.046</dc:identifier>
</item>
<item>
<title>Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37531130/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: Results suggest that the outcomes of ezetimibe combination observed in the RACING trial were consistent among patients at VHR of ASCVD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 2. doi: 10.1001/jamacardio.2023.2222. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: High-intensity statin is strongly recommended in patients at very high risk (VHR) of atherosclerotic cardiovascular disease (ASCVD). However, concerns about statin-associated adverse effects result in underuse of this strategy in practice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the outcomes of a moderate-intensity statin with ezetimibe combination in VHR and non-VHR patients with ASCVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of the Randomized Comparison of Efficacy and Safety of Lipid Lowering With Statin Monotherapy vs Statin/Ezetimibe Combination for High-Risk Cardiovascular Disease (RACING) open-label, multicenter, randomized clinical trial. The study was conducted from February 2017 to December 2018 at 26 centers in Korea. Study participants included patients with documented ASCVD. Data were analyzed from April to June 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Patients were randomly assigned to moderate-intensity statin with ezetimibe (rosuvastatin, 10 mg, with ezetimibe, 10 mg) or high-intensity statin monotherapy (rosuvastatin, 20 mg). Patients at VHR for ASCVD were defined according to the 2018 American Heart Association/American College of Cardiology guidelines.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was the 3-year outcome of cardiovascular death, coronary or peripheral revascularization, hospitalization of cardiovascular events, or nonfatal stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 3780 patients (mean [SD] age, 64 [10] years; 2826 male [75%]) in the RACING trial, 1511 (40.0%) were categorized as VHR, which was associated with a greater occurrence of the primary end point (hazard ratio [HR], 1.42; 95% CI, 1.15-1.75). There was no significant difference in the primary end point between those who received combination therapy and high-intensity statin monotherapy among patients with VHR disease (11.2% vs 11.7%; HR, 0.96; 95% CI, 0.71-1.30) and non-VHR disease (7.7% vs 8.7%; HR, 0.88; 95% CI, 0.66-1.18). The median low-density lipoprotein cholesterol (LDL-C) level was significantly lower in the combination therapy group than in the high-intensity statin group (VHR, 1 year: 57 [47-71] mg/dL vs 65 [53-78] mg/dL; non-VHR, 1 year: 58 mg/dL vs 68 mg/dL; P &lt; .001). Furthermore, in both the VHR and non-VHR groups, combination therapy was associated with a significantly greater mean change in LDL-C level (VHR, 1 year: -19.1 mg/dL vs -10.1 mg/dL; 2 years: -22.3 mg/dL vs -13.0 mg/dL; 3 years: -18.8 mg/dL vs -9.7 mg/dL; non-VHR, 1 year: -23.7 mg/dL vs -12.5 mg/dL; 2 years: -25.2 mg/dL vs -15.1 mg/dL; 3 years: -23.5 mg/dL vs -12.6 mg/dL; all P &lt; .001) and proportion of patients with LDL-C level less than 70 mg/dL (VHR, 1 year: 73% vs 58%; non-VHR, 1 year: 72% vs 53%; P &lt; .001). Discontinuation or dose reduction of the lipid-lowering drug due to intolerance occurred less frequently in the combination therapy group (VHR, 4.6% vs 7.7%; P = .02; non-VHR, 5.0% vs 8.7%; P = .001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results suggest that the outcomes of ezetimibe combination observed in the RACING trial were consistent among patients at VHR of ASCVD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03044665.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37531130/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37531130</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2222>10.1001/jamacardio.2023.2222</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37531130</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Seung-Jun Lee</dc:creator>
<dc:creator>Jung-Joon Cha</dc:creator>
<dc:creator>Woong Gil Choi</dc:creator>
<dc:creator>Wang-Soo Lee</dc:creator>
<dc:creator>Jin-Ok Jeong</dc:creator>
<dc:creator>Seonghoon Choi</dc:creator>
<dc:creator>Yoon-Haeng Cho</dc:creator>
<dc:creator>Woojung Park</dc:creator>
<dc:creator>Chang-Hwan Yoon</dc:creator>
<dc:creator>Yong-Joon Lee</dc:creator>
<dc:creator>Sung-Jin Hong</dc:creator>
<dc:creator>Chul-Min Ahn</dc:creator>
<dc:creator>Byeong-Keuk Kim</dc:creator>
<dc:creator>Young-Guk Ko</dc:creator>
<dc:creator>Donghoon Choi</dc:creator>
<dc:creator>Myeong-Ki Hong</dc:creator>
<dc:creator>Yangsoo Jang</dc:creator>
<dc:creator>Soon Jun Hong</dc:creator>
<dc:creator>Jung-Sun Kim</dc:creator>
<dc:creator>RACING Investigators</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37531130</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2222</dc:identifier>
</item>
<item>
<title>Hard Lessons From a School-Based Intervention to Improve Cardiovascular Health in Adolescence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37531101/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 2. doi: 10.1001/jamacardio.2023.2244. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37531101/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37531101</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2244>10.1001/jamacardio.2023.2244</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37531101</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Holly C Gooding</dc:creator>
<dc:creator>Liliana Aguayo</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Hard Lessons From a School-Based Intervention to Improve Cardiovascular Health in Adolescence</dc:title>
<dc:identifier>pmid:37531101</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2244</dc:identifier>
</item>
<item>
<title>School-Based Cardiovascular Health Promotion in Adolescents: A Cluster Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37531100/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: Overall, the tested school-based health promotion strategies in this randomized clinical trial had a neutral effect on the CVH of the adolescents. Although there was evidence of a marginal beneficial effect at a point halfway through implementation in the LTI group, such a benefit was not noted at 4 years. Further research is warranted into the efficacy of school-based health promotion programs.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Aug 2. doi: 10.1001/jamacardio.2023.2231. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: School-based interventions offer an opportunity for health promotion in adolescence.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess the effect of 2 multicomponent educational health promotion strategies of differing duration and intensity on adolescents' cardiovascular health (CVH).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The SI! Program for Secondary Schools is a 4-year cluster randomized clinical intervention trial conducted in 24 secondary schools from Barcelona and Madrid, Spain, from September 7, 2017, to July 31, 2021. Eligible participants were adolescents enrolled in the first grade of secondary school.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Schools and their participants were randomized to receive a health promotion intervention (SI! Program) over 4 school years (long-term intervention [LTI], 8 schools, 412 adolescents) or 2 school years (short-term intervention [STI], 8 schools, 504 adolescents) or to receive the standard curriculum (control, 8 schools, 441 adolescents).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURES: The primary end point was the between-group difference at 2 and 4 years in the change from baseline of the overall CVH score, as defined by the American Heart Association (range, 0-14 points, with a higher score indicating a healthier CVH profile). Intervention effects were tested with multilevel mixed-effects models. A complete-case intention-to-treat analysis was performed as the primary analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the randomized students, the study enrolled 1326 adolescents (684 [51.6%] boys, mean [SD] age, 12.5 [0.4] years at recruitment) with a study completion rate of 86.0%. Baseline overall CVH scores were 10.3 points in the LTI group, 10.6 points in the STI group, and 10.5 points in the control group. After 2 years, at halfway through the LTI and at the end of the STI, the difference in the CVH score change was 0.44 points (95% CI, 0.01-0.87; P = .04) between the LTI group and the control group and 0.18 points (95% CI, -0.25 to 0.61; P = .39) between the STI group and the control group. At 4 years, differences for the LTI and STI groups vs control were 0.12 points (LTI: 95% CI, -0.19 to 0.43; P = .42) and 0.13 points (STI: 95% CI, -0.17 to 0.44; P = .38). No adverse events were reported.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Overall, the tested school-based health promotion strategies in this randomized clinical trial had a neutral effect on the CVH of the adolescents. Although there was evidence of a marginal beneficial effect at a point halfway through implementation in the LTI group, such a benefit was not noted at 4 years. Further research is warranted into the efficacy of school-based health promotion programs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03504059.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37531100/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37531100</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2231>10.1001/jamacardio.2023.2231</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37531100</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Gloria Santos-Beneit</dc:creator>
<dc:creator>Juan M Fernández-Alvira</dc:creator>
<dc:creator>Anna Tresserra-Rimbau</dc:creator>
<dc:creator>Patricia Bodega</dc:creator>
<dc:creator>Amaya de Cos-Gandoy</dc:creator>
<dc:creator>Mercedes de Miguel</dc:creator>
<dc:creator>Sonia L Ramírez-Garza</dc:creator>
<dc:creator>Emily P Laveriano-Santos</dc:creator>
<dc:creator>Camila Arancibia-Riveros</dc:creator>
<dc:creator>Vanesa Carral</dc:creator>
<dc:creator>Xavier Orrit</dc:creator>
<dc:creator>Carla Rodríguez</dc:creator>
<dc:creator>Isabel Carvajal</dc:creator>
<dc:creator>Domenec Haro</dc:creator>
<dc:creator>Carles Peyra</dc:creator>
<dc:creator>Jesús Martínez-Gómez</dc:creator>
<dc:creator>Antonio Álvarez-Benavides</dc:creator>
<dc:creator>Ramón Estruch</dc:creator>
<dc:creator>Rosa M Lamuela-Raventós</dc:creator>
<dc:creator>Rodrigo Fernández-Jiménez</dc:creator>
<dc:creator>Valentín Fuster</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>School-Based Cardiovascular Health Promotion in Adolescents: A Cluster Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37531100</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2231</dc:identifier>
</item>
<item>
<title>Waist-to-height ratio for the obesity paradox in heart failure: is it a matter of fitness?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37529967/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 2:ehad503. doi: 10.1093/eurheartj/ehad503. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37529967/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37529967</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad503>10.1093/eurheartj/ehad503</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37529967</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Gen-Min Lin</dc:creator>
<dc:creator>Kun-Zhe Tsai</dc:creator>
<dc:creator>Carl J Lavie</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Waist-to-height ratio for the obesity paradox in heart failure: is it a matter of fitness?</dc:title>
<dc:identifier>pmid:37529967</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad503</dc:identifier>
</item>
<item>
<title>The fiction of the obesity paradox</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37529937/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 2:ehad504. doi: 10.1093/eurheartj/ehad504. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37529937/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37529937</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad504>10.1093/eurheartj/ehad504</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37529937</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Maya Guglin</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The fiction of the obesity paradox</dc:title>
<dc:identifier>pmid:37529937</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad504</dc:identifier>
</item>
<item>
<title>A thunder out of the blue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37529917/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230803022755&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Aug 2:ehad499. doi: 10.1093/eurheartj/ehad499. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37529917/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230803022755&v=2.17.9.post6+86293ac">37529917</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad499>10.1093/eurheartj/ehad499</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37529917</guid>
<pubDate>Wed, 02 Aug 2023 06:00:00 -0400</pubDate>
<dc:creator>Nicolas Amabile</dc:creator>
<dc:creator>Khalil Mahmoudi</dc:creator>
<dc:creator>Fréderic A Sebag</dc:creator>
<dc:date>2023-08-02</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A thunder out of the blue</dc:title>
<dc:identifier>pmid:37529917</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad499</dc:identifier>
</item>





























</channel>
</rss>